ClinicalTrials.gg
RecruitingNCT07869043Updated Nov 5, 2026

A Study to Learn About the Study Medicine Called Tilrekimig ( PF-07275315) in People With Severe Asthma

A Phase 3 interventional study of tilrekimig and Placebo in Asthma, sponsored by Pfizer. Recruiting at 12 sites in 2 countries. Open to participants aged 12 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Nov 5, 2026First site in Puerto RicoSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,100
Allocation
Randomized
Ages
12 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 24 studies in Asthma by Pfizer — 4 open to participants now, 4 under way, 2 of them phase 3. Asthma · Pfizer.

Planned enrollment
Largest of 20
1,100 · median 48
Started
2026
with 2 others
Phase 3
3 of 24
2 open now
Registered
24th of 24
by date

Among the 24 studies in Asthma by Pfizer, this one has the largest planned enrollment of the 20 interventional ones that give a count, is one of 3 that started in 2026, is one of 3 in phase 3, and was the 24th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.

Browse Asthma studies →

Open to participants now

4 of the 24 studies in Asthma by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 12 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Asthma by Pfizer, or all of them as a file.
02

Study summary

The purpose of this clinical study is to learn about the safety and effects of the study medicine (called tilrekimig) for the potential treatment of severe asthma. Asthma is a condition that makes it challenging to breathe, which negatively impacts the quality of life of people who are affected.

The study is seeking participants who:

  • Have a history of severe asthma for at least 12 months
  • Have had at least 2 asthma attacks (also known as exacerbations) within the last 12 months All participants will be given shots of study medicine or a placebo at the study clinic. Tilrekimig or the placebo will be given about every 4 weeks during the study.

The study will compare the experiences of people receiving tilrekimig to those people who receive the placebo. This will help determine if tilrekimig is safe and effective.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
12 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Must meet the following asthma criteria:

  1. History of persistent, severe asthma for at least 12 months prior to screening as defined by recognized international and / or local guidelines.
  2. Must have experienced at least 2 asthma exacerbations requiring treatment with systemic (oral or parenteral) for 3 consecutive days or more; an emergency room or urgent care visit (\<24 hours) that is due to asthma and requires use of systemic corticosteroids as noted above; or an in-patient hospitalization (an admission to an in-patient hospital or evaluation and treatment in a healthcare facility for ≥24 hours) due to asthma with within 12 months of the screening visit.
  3. Positive bronchodilator responsiveness of or FVC >10% of the participant's predicted value at 15 - 30 minutes (or as consistent with local treatment practices) after inhaling 400 µg of salbutamol/albuterol (or equivalent SABA) at least once for spirometry conducted during screening period.

    Other Inclusion Criteria:

  4. Maintenance treatment of a medium-to-high dose ICS plus an additional controller (eg, LABA) consistent with current GINA and / or local guidelines for at least 12 months (and on a stable dose for 3 months prior to screening).

Exclusion criteria

Exclusion Criteria

Participants are excluded from the study if any of the following criteria apply:

Medical Conditions:

  1. Evidence of lung disease(s) other than asthma, either clinical evidence, spirometry, or imaging (Chest X-ray, CT, MRI) within 12 months of the screening visit, as per local standard of care, including but not limited to, , other emphysematous lung disease such as alpha-1 antitrypsin disease, cystic fibrosis, emphysema, pulmonary fibrosis, Churg-Strauss syndrome, allergic bronchopulmonary aspergillosis, sarcoidosis, pulmonary embolism.
  2. Any psychiatric condition including any active suicidal ideation in the past year or suicidal behavior in the past 5 years that may increase the risk of study participation or, in the investigator's judgement, make the participant inappropriate for the study.

    Prior/Concomitant Therapy:

  3. Use of any prohibited concomitant medication(s) or unwillingness or inability to use a required concomitant medication(s). Treatment with any dose level of systemic (oral, intraarticular, or injectable) within 28 days of the screening visit.
  4. Prior or concurrent treatment with either approved or experimental biologic treatment (such as inhibitors of IL-4Ralpha, TSLP, OX40/OX40L, IL-13, IL-33 / ST2) or targeted synthetic drugs for the treatment of asthma or other type 2 inflammatory diseases, including but not limited to: AD, EoE, CRS.
  5. Prior (within 12 weeks prior to Screening Visit 1) or planned concomitant treatment with immunoglobulin supplementation (eg, IV Ig or SC Ig).
  6. Bronchial thermoplasty within the previous 24 months.

    Prior/Concurrent Clinical Study Experience:

  7. Administration of an drug product within 30 days or 5 half lives preceding the screening visit (whichever is longer). Previous participation in other tilrekimig studies or participation in studies of other investigational products (drug or vaccine) at any time during this study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,100 participants (estimated)

Study arms

  • Experimental
    Treatment Arm A Tilrekimig

    Tilrekimig

    Drug: tilrekimig

  • Placebo comparator
    Treatment Arm B Placebo

    Placebo

    Other: Placebo

Interventions

  • subcutaneous injection

  • OtherPlacebo

    subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Annualized asthma exacerbation rate over 52 weeks

    Protocol defined asthma exacerbations require treatment with systemic steroids (oral or parenteral) for 3 consecutive days or more; an emergency room or urgent care visit (\<24 hours) that is due to asthma and requires use of systemic corticosteroids as noted above; or an in-patient hospitalization (an admission to an in-patient hospital or evaluation and treatment in a healthcare facility for ≥24 hours) due to asthma.

    Time frame: Baseline through Week 52

Secondary outcomes

  1. Annualized asthma exacerbation rate over 52 weeks in participants with severe asthma and with eosinophil counts ≥300 cells/µL (ie, high eosinophil subgroup)

    Time frame: Baseline through Week 52

  2. Annualized asthma exacerbation rate over 52 weeks in participants with severe asthma and with eosinophil counts <300 cells/µL (ie, medium-to-low eosinophil subgroup)

    Time frame: Baseline through Week 52

  3. Change from baseline (CFB) in pre-bronchodilator forced expiratory volume in 1 second (FEV1) at Week 52

    Time frame: Baseline through Week 52

  4. CFB in Asthma Control Questionnaire (ACQ-5) at Week 52

    Time frame: Baseline through Week 52

  5. CFB in Asthma Quality of Life Questionnaire for 12 years and older Self-Administered (AQLQ(S)-12-SA) at Week 52

    Time frame: Baseline through Week 52

  6. Annualized asthma exacerbation rate requiring Emergency Room or Urgent Care (ER/UC) visit or hospitalization over 52 weeks

    Time frame: Baseline through Week 52

  7. Time to first asthma exacerbation

    Time frame: Baseline through Week 52

  8. CFB in weekly mean Asthma Nighttime Symptom Diary (ANSD) at Week 52

    Time frame: Baseline through Week 52

  9. CFB in weekly mean Asthma Daytime Symptom Diary (ADSD) at Week 52

    Time frame: Baseline through Week 52

  10. Clinical remission at Week 52

    Time frame: Week 52

  11. CFB in pre-bronchodilator FEV1 at all time points (other than Week 52)

    Time frame: Baseline through Week 52

  12. CFB in ACQ-5 all time points (other than Week 52)

    Time frame: Baseline through Week 52

  13. CFB in AQLQ(S)-12-SA at all time points (other than Week 52)

    Time frame: Baseline through Week 52

  14. CFB in weekly mean ANSD at all time points (other than Week 52)

    Time frame: Baseline through Week 52

  15. CFB in weekly mean ADSD at all time points (other than Week 52)

    Time frame: Baseline through Week 52

  16. CFB in pre-bronchodilator % Predicted FEV1 at all time points

    Time frame: Baseline through Week 52

  17. CFB in pre-bronchodilator forced vital capacity (FVC) at all time points

    Time frame: Baseline through Week 52

  18. CFB in pre-bronchodilator % Predicted FVC at all time points

    Time frame: Baseline through Week 52

  19. CFB in pre-bronchodilator FEV1/FVC ratio at all time points

    Time frame: Baseline through Week 52

  20. CFB in post-bronchodilator FEV1 at all time points

    Time frame: Baseline through Week 52

  21. CFB in post-bronchodilator % Predicted FEV1 at all time points

    Time frame: Baseline through Week 52

  22. CFB in post-bronchodilator FVC at all time points

    Time frame: Baseline through Week 52

  23. CFB in post-bronchodilator % Predicted FVC at all time points

    Time frame: Baseline through Week 52

  24. CFB in post-bronchodilator FEV1/FVC ratio at all time points

    Time frame: Baseline through Week 52

  25. ACQ-5 response: decrease from baseline in ACQ-5 ≥0.5 at all time points

    Time frame: Baseline through Week 52

  26. AQLQ response: increase from baseline in AQLQ(S)-12-SA ≥0.5 at all time points

    Time frame: Baseline through Week 52

  27. Time to first asthma exacerbation requiring ER/UC visit or hospitalization

    Time frame: Baseline through Week 52

  28. Clinical remission at Week 24

    Time frame: Week 24

  29. Event of ≥1 asthma exacerbation over 52 weeks

    Time frame: Baseline through Week 52

  30. Event of ≥1 asthma exacerbation associated with ER/UC visit or hospitalization over 52 weeks

    Time frame: Baseline through Week 52

  31. CFB in Patient global impression of disease severity (PGI-S) at all time points

    Time frame: Baseline through Week 52

  32. Patient global impression of change in clinical status (PGI-C) at all time points

    Time frame: Baseline through Week 52

  33. Annualized asthma exacerbation rate over 52 weeks by baseline fractional exhaled nitric oxide (FeNO) subgroup (<25 parts per billion (ppb), ≥25 to <50 ppb, ≥50 ppb)

    Time frame: Baseline through Week 52

  34. Incidence and severity of treatment-emergent adverse events (TEAEs)

    Time frame: Baseline through Week 64

  35. Incidence of treatment-emergent serious adverse events (SAEs) and TEAEs leading to discontinuation

    Time frame: Baseline through Week 64

  36. Incidence of clinical abnormalities in clinical laboratory values, vital signs or electrocardiograms

    Time frame: Baseline through Week 64

07

Study locations

4 of 12 sites recruiting
  • Asthma and Allergy Center of Chicago
    River Forest, Illinois 60305, United States
    Recruiting
  • Hannibal Regional Healthcare System, Inc.
    Hannibal, Missouri 63401, United States
    Not yet recruiting
  • Urban Health Plan
    The Bronx, New York 10459, United States
    Not yet recruiting
  • University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104, United States
    Not yet recruiting
  • Allergy and Clinical Immunology Associates
    Pittsburgh, Pennsylvania 15241, United States
    Recruiting
  • Orion Clinical Research
    Austin, Texas 78759, United States
    Recruiting
  • Southwest Medical Center (Building I) aka Southwest Family Medicine Associates
    Dallas, Texas 75235, United States
    Not yet recruiting
  • A & A Research Consultants, LLC
    Edinburg, Texas 78539, United States
    Not yet recruiting
  • Western Sky Medical Research
    El Paso, Texas 79912, United States
    Not yet recruiting
  • Pulmonary and Sleep Center of the Valley
    McAllen, Texas 78504, United States
    Not yet recruiting
  • DM Clinical Research
    Tomball, Texas 77375, United States
    Recruiting
  • Solace Clinical Research
    Bayamón, 00959, Puerto Rico
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Jun 2029, 32 months after the start.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's planned 32 months is above that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2026
First posted
Oct 9, 2026
StartActual
Sep 30, 2026
Primary completionEst.
Jun 7, 2029
CompletionEst.
Aug 30, 2029
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
9 sites added — first site in Puerto Rico. DM Clinical Research is now Recruiting
Show 9 added (8 United States, 1 Puerto Rico)
  • Asthma and Allergy Center of Chicago · River Forest, United States
  • Hannibal Regional Healthcare System, Inc. · Hannibal, United States
  • Urban Health Plan · The Bronx, United States
  • University of Oklahoma Health Sciences Center · Oklahoma City, United States
  • Southwest Medical Center (Building I) aka Southwest Family Medicine Associates · Dallas, United States
  • A & A Research Consultants, LLC · Edinburg, United States
  • Western Sky Medical Research · El Paso, United States
  • Pulmonary and Sleep Center of the Valley · McAllen, United States
  • Solace Clinical Research · Bayamón, Puerto Rico
Nov 5, 2026
Registered
First appeared on the registry
Oct 9, 2026
Show all 2 updates
  1. Nov 5, 2026
    9 sites added — first site in Puerto Rico. DM Clinical Research is now Recruiting
    Show 9 added (8 United States, 1 Puerto Rico)
    • Asthma and Allergy Center of Chicago · River Forest, United States
    • Hannibal Regional Healthcare System, Inc. · Hannibal, United States
    • Urban Health Plan · The Bronx, United States
    • University of Oklahoma Health Sciences Center · Oklahoma City, United States
    • Southwest Medical Center (Building I) aka Southwest Family Medicine Associates · Dallas, United States
    • A & A Research Consultants, LLC · Edinburg, United States
    • Western Sky Medical Research · El Paso, United States
    • Pulmonary and Sleep Center of the Valley · McAllen, United States
    • Solace Clinical Research · Bayamón, Puerto Rico
    + 1 other change: verification date
  2. Oct 9, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07869043
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Oct 9, 2026
Start date
Sep 30, 2026
Primary completion
Jun 7, 2029 (estimated)
Completion
Aug 30, 2029 (estimated)
Last update
Nov 5, 2026

Study contacts

Pfizer CT.gov Call Center
Contact
ClinicalTrials.gov_Inquiries@pfizer.com
1-800-718-1021
Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tilrekimig

Start the discussion